DIA Conference in India is Rescheduled
DIA has rescheduled its 3rd Annual Conference on Drug Discovery and Clinical Development in India, which was recently postponed due to recent violence in the area.
MUMBAI, INDIA—DECEMBER 18, 2008—
The Drug Information Association (DIA)
has rescheduled its
3rd Annual Conference on Drug Discovery and Clinical Development in India
(February 25-28, 2009; Mumbai, India).
“I would like to thank everyone for their patience and understanding for the inconvenience caused by the postponement,” says Sultan Ghani, DIA India Director. “I can assure you that DIA remains committed to its presence in India and is working with the host hotel to make sure that this meeting offers you the best educational and networking experience, under the safest and most secure conditions possible.”
Driven by the need to improve R&D productivity and efficiency and the desire to access untapped markets, global pharmaceutical companies have increasingly off shored and outsourced operations to India. A wide array of factors, however, can dictate whether such a move is successful. DIA will convene global experts from industry, academia, and regulatory for a provocative discussion on the challenges and issues facing drug discovery and clinical development in India. Topics will include:
• Development of Medical Devices: Global Regulatory Requirements
• Opportunities for Establishing Globally Centralized Laboratories in India
• India’s Patent Laws and their impact on Biopharmaceutical Industry
• India vs. ICH Regulatory Framework for Safety Reporting
• Bioinformatics and Biometrics
• Clinical Trials
• Combination Products
• Drug Delivery
• Drug Discovery
• Development of Anticancer Drugs and Biologics: PK
• Development of Biologics
• Pharmacology and Toxicology
• Pharmacovigilance
• Quality-by-Design
• Vaccine – The Challenge for Regulatory and Innovators
• Ethics in Clinical Research
About the Drug Information Association (DIA)
DIA serves more than 30,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit
or call 215-442-6100.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
